Table 1 Clinical characteristics of participants at baseline, stratified by diabetes status during follow-up.
From: The Impact of Gastric Atrophy on the Incidence of Diabetes
Participants who did not develop diabetes | Participants who developed diabetes | P | |
|---|---|---|---|
N (%) | 782 (91) | 73 (9) | |
Age (years) | 48.7 ± 11.9 | 54.9 ± 10.2 | <0.0001 |
Male (N, %) | 275 (35) | 31 (42) | 0.213 |
Body mass index (kg/m2) | 23.8 ± 3.4 | 25.1 ± 2.7 | 0.0015 |
Family history of diabetes (N, %) | 317 (41) | 32 (44) | 0.577 |
Systolic blood pressure (mmHg) | 122 ± 16 | 127 ± 17 | 0.003 |
Diastolic blood pressure (mmHg) | 78 ± 10 | 80 ± 10 | 0.1588 |
Fasting plasma glucose (mmol/L) | 4.94 ± 0.44 | 5.33 ± 0.56 | <0.0001 |
OGTT 2-h plasma glucose (mmol/L) | 6.11 ± 0.11 | 7.55 ± 1.83 | <0.0001 |
HbA1c (mmol/mol) | 38 ± 4.4 | 41 ± 4.4 | <0.0001 |
HbA1c (%) | 5.6 ± 0.4 | 5.9 ± 0.4 | <0.0001 |
HOMA2-IR | 0.75 (0.5–1.1) | 1.1 (0.84–1.43) | <0.0001 |
HOMA2%B | 80.65 (62.6–104.8) | 90.9 (68.6–109.5) | 0.2377 |
Total cholesterol (mmol/L) | 5.00 ± 0.91 | 5.34 ± 0.96 | 0.0017 |
Triglyceride (mmol/L) | 0.99 (0.71–1.44) | 1.36 (0.88–1.80) | 0.0002 |
HDL cholesterol (mmol/L) | 1.35 ± 0.34 | 1.29 ± 0.31 | 0.2271 |
LDL cholesterol (mmol/L) | 3.00 ± 0.83 | 3.34 ± 0.96 | 0.0011 |
Uric acid (μmol/L) | 321 ± 89 | 345 ± 77 | 0.0651 |
hsCRP (nmol/L) | 0.76 (0.38–1.43) | 1.24 (0.67–2.76) | 0.0005 |
H. pylori IgG titer (U/mL) | 5 (1.8–38.9) | 4.1 (1.6–33.3) | 0.5778 |
H. pylori serostatus | 0.699 | ||
Negative (N, %) | 462 (59) | 47 (64) | |
Borderline positive (N, %) | 37 (5) | 3 (4) | |
Positive (N, %) | 283 (36) | 23 (32) | |
PG I (ng/mL) | 49.4 (39.6–65.7) | 52.6 (40.6–65.4) | 0.1553 |
PG II (ng/mL) | 50.6 (38–66.4) | 56.2 (43.6–71.1) | 0.8807 |
PG I/II ratio | 4.59 (3.67–5.47) | 4.75 (4.21–5.57) | 0.1714 |
Gastric atrophy (N, %) | 75 (9) | 3 (4) | 0.139 |
